Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.

KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

KRO posts a wider-than-expected Q3 loss as lower TiO2 prices and weak demand hit sales, with volumes under pressure.

SR's Q4 loss widens, but rising revenues and stronger full-year earnings underscore improving momentum ahead.

SR's Q4 loss widens, but rising revenues and stronger full-year earnings underscore improving momentum ahead.

PBF posts narrower Q3 loss as cost cuts lift results, though revenues and throughput volumes fall year over year.

PBF posts narrower Q3 loss as cost cuts lift results, though revenues and throughput volumes fall year over year.

GOOGL's surging AI-driven search and cloud momentum fuels standout gains and supports its premium valuation.

GOOGL's surging AI-driven search and cloud momentum fuels standout gains and supports its premium valuation.